PEPFAR/State Department Deal History & Licensing Activity
PEPFAR/State Department is a life sciences. Over the past three years, PEPFAR/State Department has been involved in 1 licensing and acquisition transaction, with a primary focus on Small Molecules (2 deals).
Deals (12mo)
1
Active Trials
0
Top Modality
Small Molecules
Focus Area
Infectious Disease
PEPFAR/State Department Recent Deal Activity
Licensing, acquisition, and partnership transactions involving PEPFAR/State Department in the past 12 months.
| Asset | Partner | Modality | Phase | Type | Date |
|---|---|---|---|---|---|
| lenacapavir | Gilead Sciences | Small Molecules | Unknown | license | Jun 2025 |
PEPFAR/State Department Pipeline Focus
Therapeutic areas and modalities where PEPFAR/State Department is most active based on deal history and clinical trial data.
Therapeutic Areas
Modalities
PEPFAR/State Department Strategic Signals
Key indicators of PEPFAR/State Department's licensing and acquisition strategy, including patent expirations, pipeline gaps, and strategic priorities.
Strategic Profile
Acquisition Appetite
See How Your Asset Matches PEPFAR/State Department's Portfolio
Use our deal calculator to benchmark upfront payments, milestones, and royalties for Infectious Disease assets — powered by data from 3,500+ real biopharma transactions.
Related Intelligence
Infectious Disease Deal Benchmarks
Market sizing, deal terms, and competitive landscape for infectious disease
Small Molecules Benchmarks
Upfront, milestone, and royalty benchmarks for small molecules deals
Deal Pulse
Track the latest biopharma licensing and acquisition deals across all therapeutic areas
All Company Profiles
Browse 850+ biotech and pharma company profiles with deal history and pipeline data
2026 Deal Benchmarks Report
Industry-wide analysis of deal terms, trends, and market dynamics
About PEPFAR/State Department Licensing & Deal Activity
PEPFAR/State Department is a life sciences company that has been actively engaged in licensing transactions across the biopharma landscape. With 1 deal over the past three years, PEPFAR/State Department ranks among the actively acquisitive companies tracked by Ambrosia Ventures.
Key therapeutic areas of focus for PEPFAR/State Department include Infectious Disease (2 deals and trials). In terms of modality, PEPFAR/State Department has shown particular interest in small molecules.
Ambrosia Ventures tracks deal terms, pipeline data, patent expirations, and competitive positioning for PEPFAR/State Department and 850+ other biopharma companies. Use our deal calculator to benchmark your asset against PEPFAR/State Department's historical deal terms, or explore all company profiles to find the best partner match for your pipeline.